Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

891525

registered interest
date	25/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Department of Health and Social Care: Sick Leave
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of his Department's staff have had days off sick because of mental illness or stress in each of the last three years; and how many days off that amounted to in each of those years.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	138036
answer	answer is ministerial correction date of answer 30/04/2018 answer text <p>Departmental information systems do not record sickness absence relating to stress as a distinct category. Within the broader category that includes all mental health issues, the following table shows how many and the proportion of staff who have had days off sick and the total working days lost within that category in each of the last three years.</p><p> </p><table><tbody><tr><td><p>Category</p></td><td><p>2015</p></td><td><p>2016</p></td><td><p>2017</p></td></tr><tr><td><p>Number of staff members who had days off sick due to mental illness</p></td><td><p>88</p></td><td><p>82</p></td><td><p>44</p></td></tr><tr><td><p>Proportion of staff who had days off due to mental illness</p></td><td><p>4%</p></td><td><p>4%</p></td><td><p>2%</p></td></tr><tr><td><p>Total days lost due to mental illness</p></td><td><p>2,194</p></td><td><p>1,852</p></td><td><p>1,832</p></td></tr></tbody></table><p> </p><p>Note:</p><p>Data as at 31 December for each year.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 30/04/2018 15:40:06 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

890118

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to maintain competition in clinical trials after the UK leaves the EU.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	137168
answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>The Government has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation, including clinical trials. Every Government department, including the Department of Health and Social Care, is planning to deliver a smooth exit under any scenario, which includes preparing the UK for the future economic partnership we hope to negotiate with the European Union, as well as the very unlikely scenario in which no mutually satisfactory agreement can be reached and the UK exits without a deal.</p><p> </p><p>If the clinical trials regulation comes into force during the implementation period, as it is currently expected to do in March 2020, it will apply to the UK. The withdrawal agreement and implementation Bill will give effect to the implementation period in domestic law and will allow regulations to continue to apply in the UK for this time-limited period. If this opportunity does not come to pass, we will give priority to taking the steps necessary to bring into UK law, without delay, all relevant parts of the EU regulation that are within the UK’s control, so that those planning clinical research can do so with certainty.</p><p> </p><p>The UK is already a preferred destination for EU and global clinical trials. The Government has been clear that it is in the interest of patients and the life sciences industry across Europe for the UK and EU to find a way to continue cooperation in the field of clinical trials, and for continued sharing of data and information, even if our precise relationship with the EU will by necessity change. As part of the Department’s Exiting the EU programme, officials are working to ensure appropriate coordination across a number of projects relating to research and clinical trials including workforce, regulations, funding and rare diseases.</p><p> </p><p>The National Institute for Health Research (NIHR) provides the support, expertise and facilities that the National Health Service needs to undertake world-leading clinical trials funded by the NIHR, and other public, charity and life sciences industry partners, by funding a range of infrastructure facilities and the Clinical Research Network. Through NIHR and its partners, and by close collaboration with the life sciences sector and industry, the Government will ensure that the UK remains one of the best places in the world for research, science and innovation.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:21:29 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

890119

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Clinical Trials: EU Law
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to ensure continued access to the EU clinical trials portal and database after the UK leaves the EU.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	137169
answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>If the Clinical Trials Regulation comes into force during the Implementation Period, as it is currently expected to in March 2020, it will apply to the United Kingdom. The Withdrawal Agreement and Implementation Bill will give effect to the implementation period in domestic law and will allow regulations to continue to apply in the UK for this time-limited period.</p><p> </p><p>If this opportunity does not come to pass, we will give priority to taking the steps necessary to bring into UK law, without delay, all relevant parts of the European Union regulation that are within the UK’s control, so that those planning clinical research can do so with certainty.</p><p> </p><p>The two key elements of the Regulation that are outside of the UK’s control, and this guarantee does not therefore cover, are the use of a shared central IT portal and database and participation in the single assessment model, both of which require a negotiated UK/EU agreement regarding UK involvement post-Brexit. We cannot pre-empt these negotiations, nor can we disadvantage the UK’s position in these negotiations by giving any further guarantees at this time.</p><p> </p><p>Regardless of the outcome of a Brexit deal and the application date of the Regulation, the UK is committed to offering a competitive service for clinical trial assessment. This covers regulatory approval from the Medicines and Health products Regulatory Agency (MHRA) as well as services from the Health Research Authority, ethics services, the National Institute for Health Research and the National Health Service. The current regulatory approval legislation will stay in place until such time as any changes are needed so there will be no interruption in UK clinical trials approval.</p><p> </p><p>In the event that the UK is not part of the EU shared central IT portal and database and therefore trials to be run wholly or in part in the UK are not submitted through the EU portal, it will still be perfectly possible for sponsors to run multistate trials involving the UK. Sponsors would have to apply to the MHRA as well as to the EU concerned states. However, MHRA would take every effort to ensure that a parallel submission to the MHRA was as streamlined and efficient as possible and that we were able to match or better the European timeline for assessment. MHRA and UK ethics committees are already internationally recognised for their robust yet timely assessment of trial applications and the UK is currently one of the most competitive Member States for timelines.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:20:11 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

890120

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to support the maintenance of links between regulators, research ethics committees, researchers and the pharmaceutical industry in the UK and the European Medicines Agency after the UK leaves the EU.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	137170
answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>The Department has always made clear its intention to retain a close working partnership with the European Union, in the interest of ensuring patients continue to have timely access to safe medicines and medical innovations. This includes maintaining a strong working relationship with the European Medicines Agency on all aspects of the life sciences sector.</p><p> </p><p>It is of mutual benefit for the EU to collaborate closely with such a well-developed life sciences market in the United Kingdom. Both sides will always be stronger by working in partnership.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 26/04/2018 11:23:42 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

890121

registered interest
date	23/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will negotiate a deal with the EU to allow mutual recognition agreements on the manufacture and distribution of investigational medicinal products and pharmacovigilance services after the UK leaves the EU.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	137171
answer	answer is ministerial correction date of answer 26/04/2018 answer text <p>From 30 March 2019, the United Kingdom will no longer be a Member of the European Union. However, under the terms of the implementation period agreement regulatory standards and market access for all medicines will continue on current terms.</p><p> </p><p>Regarding the future relationship, the Prime Minister’s Mansion House speech outlined that we will also explore the terms on which the UK could remain part of the European Medicines Agency. While it would not be appropriate to pre-judge the outcome of the negotiations, we will discuss with the EU and Member States how best to continue cooperation in medicines regulation more broadly, including manufacturing and distribution of investigational medicinal products and pharmacovigilance services.</p><p> </p><p>Our overall aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines and be assured that their safety is protected through the strongest regulatory framework and continued sharing of data.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 26/04/2018 16:07:42 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

887287

registered interest
date	19/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diseases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many cases of (a) tuberculosis, (b) rickets and (c) measles were recorded in each month in the last 12 months.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	136851
answer	answer is ministerial correction date of answer 24/04/2018 answer text <p>The data for cases of tuberculosis (TB) for the last 12 months are not available in the format requested.</p><p> </p><p>The most recent provisional data for the number and rate of TB cases notified in England in 2017 are available here:</p><p><a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/693328/TB_ad_hoc_statistics_March_2018.pdf" target="_blank">https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/693328/TB_ad_hoc_statistics_March_2018.pdf</a></p><p>Data on the number of cases of rickets recorded in England for each of the last 12 months are not available in the format requested.</p><p> </p><p>The latest data available on the number of confirmed cases of rickets in England can be found here:</p><p><a href="https://digital.nhs.uk/data-and-information/find-data-and-publications/supplementary-information/2018-supplementary-information-files/count-of-finished-admission-episodes-faes-with-a-primary-or-secondary-diagnosis-of-scurvy-rickets-and-malnutrition-supplementary-information" target="_blank">https://digital.nhs.uk/data-and-information/find-data-and-publications/supplementary-information/2018-supplementary-information-files/count-of-finished-admission-episodes-faes-with-a-primary-or-secondary-diagnosis-of-scurvy-rickets-and-malnutrition-supplementary-information</a></p><p>Data on the number of cases of measles recorded in England for each of the last 12 months are not available in the format requested.</p><p> </p><p>The latest data available on the number of confirmed measles cases in England can be found here:</p><p><a href="https://www.gov.uk/government/publications/measles-mumps-and-rubella-laboratory-confirmed-cases-in-england-2017." target="_blank">https://www.gov.uk/government/publications/measles-mumps-and-rubella-laboratory-confirmed-cases-in-england-2017.</a></p> answering member constituency Winchester answering member printed Steve Brine question first answered 24/04/2018 15:30:00 answering member 4067 label Biography information for Steve Brine
tabling member	4036 label Biography information for Luciana Berger

887288

registered interest
date	19/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicines and Healthcare products Regulatory Agency
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to ensure that the Medicines and Healthcare products Regulatory Agency will be supported to maintain its status as a world-leading regulator.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	136852
answer	answer is ministerial correction date of answer 24/04/2018 answer text <p>The Medicines and Healthcare products Regulatory Agency (MHRA) is a strong national regulator with substantial capacity and expertise to regulate and evaluate the safety of our medicines and medical devices. The Agency is recognised globally for its expertise in licensing, inspections and batch release, and their pharmacovigilance regime is globally recognised and respected. Furthermore, the Agency is considered a leader within the European Union regulatory framework.</p><p> </p><p>The Government has been clear about our desire to negotiate a close relationship with the EU, including exploring with the EU the terms on which the United Kingdom could remain part of the European Medicines Agency. This was reinforced by my Rt. hon. Friend the Prime Minister in her Mansion House speech of 2 March. Nevertheless the MHRA will seek to become an even more influential partner internationally in its own right, and is committed to being a global leader, focusing on raising the quality of standards across the world.</p><p> </p><p>The Agency is also committed to continuing cooperation with international fora, including the International Medical Device Regulators Forum, the International Coalition of Medicines Regulatory Authorities and the International Council for Harmonisation of Technical Requirements for Human Use. The form that UK participation takes in some of these groups will depend on the outcome of the Future Economic Partnership negotiations with the EU.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 24/04/2018 13:34:24 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger

887289

registered interest
date	19/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Illness: Personal Health Budgets
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 29 January 2018 to Question 124498, on Mental Illness: Personal Health Budgets, how many people were in receipt of a personal health budget specifically to meet mental health needs in 2016-17.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	136853
answer	answer is ministerial correction date of answer 24/04/2018 answer text <p>In 2016/17 1,037 people had personal health budgets specifically to meet mental health needs.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 24/04/2018 11:20:54 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

887291

registered interest
date	19/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medicine: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the effect of leaving the EU on early-phase clinical research.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	136855
answer	answer is ministerial correction date of answer 24/04/2018 answer text <p>The Government has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation, including on early phase research and clinical trials. Every Government department, including the Department of Health and Social Care, is planning to deliver a smooth exit under any scenario, which includes preparing the UK for the future economic partnership we hope to negotiate with the European Union, as well as the very unlikely scenario in which no mutually satisfactory agreement can be reached and the UK exits without a deal.</p><p> </p><p>The UK is already a preferred destination for EU and global clinical trials – where much early phase research is concentrated. The Government has been clear that it is in the interest of patients and the Life Sciences industry across Europe for the UK and EU to find a way to continue cooperation in the field of clinical trials, and for continued sharing of data and information, even if our precise relationship with the EU will by necessity change. The Government is committing to being as aligned with the new EU Clinical Trials Regulation as we possibly can be, subject to the outcome of the future relationship negotiation.</p><p> </p><p>The National Institute for Health Research (NIHR) provides the support, expertise and facilities that the National Health Service needs to undertake world-leading early-phase research funded by the NIHR, and other public, charity and life sciences industry partners, by funding a range of infrastructure facilities. Through NIHR and its partners, and by close collaboration with the life sciences sector and industry, the Government will ensure that the UK remains one of the best places in the world for research, science and innovation.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 24/04/2018 11:23:03 answering member 4008 label Biography information for Dame Caroline Dinenage
tabling member	4036 label Biography information for Luciana Berger

886397

registered interest
date	18/04/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Mental Health Services: Children and Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timetable is for the funding allocated to CAHMS by NHS England in January 2018 for over 130 new CAHMS beds to be released.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	136592
answer	answer is ministerial correction date of answer 23/04/2018 answer text <p>During 2017/18, NHS England commissioned 113 new child and adolescent mental health services in-patient beds. The revenue funding required to support these beds was allocated during 2017/18 and 2018/19.</p><p> </p><p>There are plans to commission around 100 further new beds over the next six months, from April 2018. The revenue will be allocated on a phased basis as the beds open.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 23/04/2018 13:48:26 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	4036 label Biography information for Luciana Berger